These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3473646)

  • 21. Effect of prolonged bromhexine therapy on Sjögren's syndrome.
    Nahir AM; Scharf Y; Ben-Aryeh H; Szargel R; Gutman D; Zonis S; Scharf J
    Isr J Med Sci; 1981 Jun; 17(6):403-6. PubMed ID: 6167531
    [No Abstract]   [Full Text] [Related]  

  • 22. Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva.
    Manthorpe R; Frost-Larsen K; Høj L; Isager H; Prause JU
    Scand J Rheumatol; 1981; 10(3):177-80. PubMed ID: 7027431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of sulphasalazine as a treatment modality in Sjögren's disease in NZB/NZW F1 hybrid mice.
    Yeoman CM; Franklin CD
    Clin Exp Rheumatol; 1996; 14(1):53-7. PubMed ID: 8697658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
    Rudofsky UH; Evans BD; Balaban SL; Mottironi VD; Gabrielsen AE
    Lab Invest; 1993 Apr; 68(4):419-26. PubMed ID: 8479150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sialochemistry in evaluating bromhexine treatment of Sjögren's syndrome.
    Nahir AM; Aryeh HB; Szargel R; Scharf Y; Gutman D; Blaustein Y; Scharf Y
    Br Med J; 1979 Oct; 2(6194):833. PubMed ID: 509119
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Sjögren's syndrome: an overview.
    Manthorpe R; Prause JU
    Scand J Rheumatol Suppl; 1986; 61():237-41. PubMed ID: 3296150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.
    Okudaira H; Terada E; Okudaira K
    Prog Clin Biol Res; 1987; 229():157-74. PubMed ID: 3601985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Crescentic glomerulonephritis and primary Gougerot-Sjögren syndrome].
    Dussol B; Tsimaratos M; Bolla G; Harlé JR; Brunet P; Casanova P; Weiller PJ; Berland Y
    Nephrologie; 1994; 15(4):295-8. PubMed ID: 7984249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress and regression within primary Sjögren's syndrome.
    Manthorpe R; Bredberg A; Henriksson G; Larsson A
    Scand J Rheumatol; 2006; 35(1):1-6. PubMed ID: 16467033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjögren's syndrome-like autoimmune exocrinopathy.
    Brayer J; Lowry J; Cha S; Robinson CP; Yamachika S; Peck AB; Humphreys-Beher MG
    J Rheumatol; 2000 Aug; 27(8):1896-904. PubMed ID: 10955330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effects of nandrolone decanoate, tibolone, lynestrenol and ethylestrenol on Sjögren's syndrome-like disorder in NZB/W mice.
    Verheul HA; Schot LP; Schuurs HW
    Clin Exp Immunol; 1986 May; 64(2):243-8. PubMed ID: 3742875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human chorionic gonadotropin prevents Sjögren's syndrome-like exocrinopathy in mice.
    Li N; Shigihara T; Tzioufas AG; Notkins AL; Yoon JW; Jun HS
    Arthritis Rheum; 2007 Jul; 56(7):2211-5. PubMed ID: 17599739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of bromhexine on tear lysozome level in keratoconjunctivitis sicca.
    Scharf JM; Obedeanu N; Meshulam T; Nahir M; Merzbach D; Scharf JA; Zonis S
    Am J Ophthalmol; 1981 Jul; 92(1):21-3. PubMed ID: 7258276
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic effect of early thymic irradiation in (NZB x NZW)F1 mice, associated with a selective decrease in the levels of IgG3 and gp70-anti-gp70 immune complexes.
    Erausquin C; Merino R; Izui S; Fernandez-Sueiro L; Saez F; Fernandez F; Rodriguez-Valverde V; Merino J
    Cell Immunol; 1995 Apr; 161(2):207-12. PubMed ID: 7697731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceleration of glomerulonephritis in NZB x NZW mice by early immunization with DNA and injection of bacterial lipopolysaccharide. Experimental approach to the treatment of lupus nephritis by use of the accelerated model of NZB x NZW mouse disease.
    Fournie GJ; Minh MG; Mignon-Conte MA; Hass S; Lambert PH; Conte JJ
    J Clin Lab Immunol; 1980 Sep; 4(2):103-6. PubMed ID: 7441709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Keratoconjunctivitis sicca.
    Baum JL
    Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol; 1976; 81(4 Pt 1):OP619-23. PubMed ID: 960384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Our experience with the treatment of ocular changes in Sjögren's syndrome].
    Portacha L
    Klin Oczna; 1984 Nov; 86(11):485-6. PubMed ID: 6535881
    [No Abstract]   [Full Text] [Related]  

  • 39. Genetic studies of autoimmunity in New Zealand mice. IV. Contribution of NZB and NZW genes to the spontaneous occurrence of retroviral gp70 immune complexes in (NZB X NZW)F1 hybrid and the correlation to renal disease.
    Maruyama N; Furukawa F; Nakai Y; Sasaki Y; Ohta K; Ozaki S; Hirose S; Shirai T
    J Immunol; 1983 Feb; 130(2):740-6. PubMed ID: 6217253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance defects in New Zealand Black and New Zealand Black X New Zealand White F1 mice.
    McCoy KL; Kendrick L; Chused TM
    J Immunol; 1986 Feb; 136(4):1217-22. PubMed ID: 3944456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.